foscarbidopa/foslevodopa; levodopa/carbidopa phosphate (Vyalev)
Jump to navigation
Jump to search
Indications
- continuous subcutaneous drug treatment for Parkinson's disease (FDA-approved Oct 2024)
Dosage
- delivered subcutaneously via a continuous-delivery infusion pump
- supplemental vitamin B6 may be prudent[3]
Adverse effects
- infusion-site erythema (27%)
- pain (26%)
- cellulitis (19%); catheter-site & infusion-site cellulitis uncommon [[2]
- edema (12%)[2]
- seizures may occur with vitamin B6 deficiency[3]
Clinical significance
- may increase "on" time without increasing dyskinesia[2]
More general terms
Components
References
- ↑ Rosebraugh M et al. Foslevodopa/foscarbidopa: A new subcutaneous treatment for Parkinson's disease. Ann Neurol 2021 Mar 26; [e-pub]. PMID: https://pubmed.ncbi.nlm.nih.gov/33772855 https://onlinelibrary.wiley.com/doi/10.1002/ana.26073
- ↑ 2.0 2.1 2.2 Soileau MJ et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: A randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 2022 Dec; 21:1099 PMID: https://pubmed.ncbi.nlm.nih.gov/36402160 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00400-8/fulltext
- ↑ 3.0 3.1 3.2 George J FDA Warns of Seizure Risk With Some Parkinson's Drugs. New carbidopa/levodopa labels will state that seizures linked to vitamin B6 deficiency can occur MedPage Today. March 20, 2026 https://www.medpagetoday.com/neurology/parkinsonsdisease/120421